According to a recent report, Liberal MP Belinda Stronach, who is combating breast cancer, went to California last June for some of her breast cancer treatment.

Greg MacEachern, Stronach’s representative, told that the former cabinet minister had a later-stage surgical operation in the US after her Toronto physicians referred her.

Baltimore: Dr. Martin D. Abeloff, an authority on the breast cancer treatment and chief oncologist at Johns Hopkins, died on Friday in Baltimore. He was 65 years old.

Mr. Abeloff guided the Kimmel Comprehensive Cancer Center at Johns Hopkins University for the last 15 years.

Vanessa Wasta, a representative for the cancer center said that Abeloff’s death followed a fight with leukemia, a type of cancer.

Wasta added that his leukemia was growing slowly, but his condition got worsened this past spring.

Alan O. Trounson, embryonic stem cell research and invitro fertilization specialist, from Australia, has been nominated as president of the California Institute for Regenerative Medicine (CIRM), that is at the top of California’s stem cell program worth $3 billion.

Mr. Trounson has a glorious record in research & investigation, management skills and confronting Australia's controversial politics circling embryonic stem cell research.

Trounson is well-known through-out the world for his work in stem cell investigation and human fertilization.

Washington, Sept 16: Negotiations between Britney Spears’ camp and Emmy producers have ended, as Spears has refused to appear on the awards event scheduled for Sept 16, 2007.

Ryan Seacrest, the show’s host said that talks are on to rope in the ‘Toxic’ star.

“I’m trying to figure out how Britney fits into the context of television’s biggest night…I don’t know anything about it… it’s a possible first step,” US magazine quoted Ryan Seacrest, the show’s host, as saying.

Washington: The U.S. Food and Drug Administration has approved 15 new blood typing examinations intended to perk up the safety of blood transfusion.

The tests that were previously unavailable in the US are called blood grouping reagents.

The FDA has stated that the tests find out the blood type of blood donors, a vital step in guaranteeing safe blood transfusion for patients. If incompatible blood is administered to a patient, it may cause a grave and possibly deadly reaction.